Hypoxia-inducible factor-1α expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer

Clinical Cancer Research

Volumn 12, Issue 15, 2006, Pages 4562-4568

  Generali, Daniele ^b,c   Berruti, Alfredo ^d   Brizzi, Maria P ^d   Campo, Leticia ^b   Bonardi, Simone ^c   Wigfield, Simon ^b   Bersiga, Alessandra ^c   Allevi, Giovanni ^c   Milani, Manuela ^c   Aguggini, Sergio ^c   Gandolfi, Valeria ^c   Dogliotti, Luigi ^d   Bottini, Alberto ^c   Harris, Adrian L ^b   Fox, Stephen B ^a,e  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CREMONA HOSPITAL   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CARBONATE DEHYDRATASE IX; CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; METHOTREXATE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RECURRENCE; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33748037026     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2690     Document Type: Article

References (34)

1. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-76.
2. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000;88:1474-80.
3. Harris AL. Hypoxia-a key regulatory factor in tumor growth. Nat Rev Cancer 2002;2:38-47.
4. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 1999;59:5830-5.
5. Bos R, Zhong H, Hanrahan CF, et al. Levels of hypoxia-inducible factor-1α during breast carcinogenesis. J Natl Cancer Inst 2001;93:309-14.
6. Schindl M, Schoppmann SF, Samonigg H, et al. Over-expression of hypoxia-inducible factor 1α is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002;8:1831-7.
7. Gruber G, Greiner RH, Hlushchuk R, et al. Hypoxia-inducible factor 1α in high-risk breast cancer: an independent prognostic parameter? Breast Cancer Res 2004;6:R191-8.
8. Mori I, Yang Q, Kakudo K. Predictive and prognostic markers for invasive breast cancer. Pathol Int 2002;52: 186-94.
9. Henderson IC, Patek AJ. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat 1998;52: 261-88.
10. Bottini ABA, Berruti A, Brizzi MP, et al. Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single institution phase III trial. Endocr Relat Cancer 2005;12:383-92.
11. Zambetti M, Giacobone A, Terenziani M, et al. Sequential adriamycin and CMF in metastatic breast cancer. Oncologist 1997;2:223-7.
12. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
13. Bottini A, Berruti A, Bersiga A, et al. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 2000;6:2751-8.
14. Pastorekova S, Zavadova Z, Kostal M, Babusikova O, Zavada J. A novel quasi-viral agent, MaTu, is a two-component system. Virology 1992;187:620-6.
15. Talks KL, Turley H, Gatter KC, et al. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000; 157:411-21.
16. Chia SK, Wykoff CC, Watson PH, et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 2001;19:3660-8.
17. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
18. Haugland HK, Vukovic V, Pintilie M, et al. Expression of hypoxia-inducible factor-1α in cervical carcinomas: correlation with tumor oxygenation. Int J Radiat Oncol Biol Phys 2002;53:854-61.
19. Burri P, Djonov V, Aebersold DM, et al. Significant correlation of hypoxia-inducible factor-1α with treatment outcome in cervical cancer treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 2003;56: 494-501.
20. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G. Expression of hypoxia-inducible factor 1 ain epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001;7:1661-8.
21. Koukourakis MI, Giatromanolaki A, Skarlatos J, et al. Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res 2001;61:1830-2.
22. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 2001;61:7992-8.
23. Bos R, van der Groep P, Greijer AE, et al. Levels of hypoxia-inducible factor-1α independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003;97:1573-81.
24. Harrison L, Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 2004;9:31-40.
25. Teicher BA, Lazo JS, Sartorelli AC. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 1981;41:73-81.
26. Erler JT, Cawthorne CJ, Williams KJ, et al. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 2004;24:2875-89.
27. Bottini A, Berruti A, Brizzi MP, et al. Pretreatment haemoglobin levels significantly predict the tumor response to primary chemotherapy in human breast cancer. Br J Cancer 2003;89:977-82.
28. Taghian AG, Abi-Raad R, Assaad SI, et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J Clin Oncol 2005;23:1951-61.
29. Mollica F, Jain RK, Netti PA. A model for temporal heterogeneities of tumor blood flow. Microvasc Res 2003;65:56-60.
30. Minko T, Kopeckova P, Pozharov V, Jensen KD, Kopecek J. The influence of cytotoxicity of macromolecules and of VEGF gene modulated vascular permeability on the enhanced permeability and retention effect in resistant solid tumors. Pharm Res 2000;17: 505-14.
31. Gritfon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 1999; 59:3776-82.
32. Wartenberg M, Ling FC, Muschen M, et al. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J 2003;17:503-5.
33. Jung F, Haendeler J, Hoffmann J, et al. Hypoxic induction of the hypoxia-inducible factor is mediated via the adaptor protein Shc in endothelial cells. Circ Res 2002;91:38-45.
34. Rafajova M, Zatovicova M, Kettmann R, Pastorek J, Pastorekova S. Induction by hypoxia combined with low glucose or low bicarbonate and high posttranslational stability upon reoxygenation contribute to carbonic anhydrase IX expression in cancer cells. Int J Oncol 2004;24:995-1004.